Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Rating) was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 35,300 shares, a drop of 59.2% from the April 15th total of 86,600 shares. Based on an average daily volume of 17,600 shares, the short-interest ratio is currently 2.0 days.
A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its holdings in shares of Acurx Pharmaceuticals by 149.8% in the 1st quarter. BlackRock Inc. now owns 16,699 shares of the company’s stock valued at $55,000 after purchasing an additional 10,014 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Acurx Pharmaceuticals by 75.0% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 7,000 shares of the company’s stock valued at $30,000 after purchasing an additional 3,000 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Acurx Pharmaceuticals in the 3rd quarter valued at $155,000. Finally, Tocqueville Asset Management L.P. raised its holdings in shares of Acurx Pharmaceuticals by 91.0% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 19,100 shares of the company’s stock valued at $98,000 after purchasing an additional 9,100 shares in the last quarter. 0.72% of the stock is owned by institutional investors.
Shares of NASDAQ:ACXP traded up $0.10 during mid-day trading on Friday, reaching $2.71. 32,833 shares of the company were exchanged, compared to its average volume of 11,229. Acurx Pharmaceuticals has a 1 year low of $2.61 and a 1 year high of $8.74. The firm has a market cap of $27.80 million and a price-to-earnings ratio of -1.78. The firm’s 50-day simple moving average is $3.65 and its 200 day simple moving average is $4.14.
About Acurx Pharmaceuticals (Get Rating)
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
- Get a free copy of the StockNews.com research report on Acurx Pharmaceuticals (ACXP)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.